Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
cancer
14
×
clinical trials
14
×
life sciences
national blog main
biotech
boston blog main
boston top stories
national top stories
san francisco blog main
new york blog main
san francisco top stories
national
europe blog main
fda
new york top stories
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
ipo
roche
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer drugs
deals
europe top stories
investing
novartis
pfizer
What
ipo
medicines
cancer
drug
bio
roundup
therapeutics
new
research
announced
black
brings
companies
crispr
diamond
fda
focus
forms
growing
leading
life
loss
market
medicine
patients
pipeline
plans
proteins
revolution
science
sets
targets
tests
type
years
access
acquisitions
adding
advanced
advantages
Language
unset
14
×
Current search:
" clinical trials "
×
cancer
×
unset
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug